Show simple item record

dc.contributor.authorYilmaz Ö.
dc.contributor.authorÖzden M.G.
dc.contributor.authorAydin F.
dc.contributor.authorSentürk N.
dc.contributor.authorCantürk T.
dc.contributor.authorTuranli A.Y.
dc.date.accessioned2020-06-21T09:27:40Z
dc.date.available2020-06-21T09:27:40Z
dc.date.issued2010
dc.identifier.issn1300-2996
dc.identifier.urihttps://hdl.handle.net/20.500.12712/4129
dc.description.abstractCetuximab, is an IgG1 chimeric monoclonal antibody type of epidermal growth factor receptor (EGFR). It is most commonly prescribed for metastatic colorectal cancer, administered alone or in combination with irinotecan-based chemotherapy regimens (Lee et al., 2008; Segaert et al., 2005; Segaert and Cutsem 2005; Scope et al., 2009). Acneiform eruption is the most common adverse effect with 80% of incidence (Segaert and Cutsem 2005; Lee et al., 2008). We report two cases of severe acneiform eruption induced by cetuximab with metastatic colorectal cancer. © 2010 OMU All rights reserved.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcneiform eruptionen_US
dc.subjectCetuximaben_US
dc.subjectChemotherapyen_US
dc.subjectColorectal canceren_US
dc.subjectIrinotecanen_US
dc.subjectSide effecten_US
dc.titleAcneiform skin lesions associated with cetuximab therapy: Report of two casesen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume27en_US
dc.identifier.issue3en_US
dc.identifier.startpage118en_US
dc.identifier.endpage119en_US
dc.relation.journalJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record